Announcements Trials

Browse Landscape

Phase

Phase 2 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 5 Neoplasms 4 Small Cell Lung Carcinoma 2 Squamous Cell Carcinoma of Head and Neck 1 Non-Muscle Invasive Bladder Neoplasms 1 Neoplasm Metastasis 1 Myeloproliferative Disorders 1 Lung Neoplasms 1 Leukemia, Myeloid, Acute 1 Infections 1 Colorectal Neoplasms 1 Colonic Neoplasms 1 COVID-19 1 Breast Neoplasms 1 Anemia, Refractory, with Excess of Blasts 1

Interventions

Oxaliplatin 67 Capecitabine 60 Fluorouracil 58 Bevacizumab 54 Gemcitabine 51 Paclitaxel 50 Leucovorin 50 Irinotecan 40 Docetaxel 39 Carboplatin 39 Cisplatin 38 pembrolizumab 37 Nivolumab 37 Cetuximab 35 Sunitinib 25 Trastuzumab 24 Radiosurgery 24 Radiotherapy 21 Doxorubicin 21 Cyclophosphamide 21 Panitumumab 20 Drug Therapy 19 Pemetrexed 18 Everolimus 18 Sorafenib 17 Interleukin-2 16 Fulvestrant 16 Albumin-Bound Paclitaxel 16 atezolizumab 15 Erlotinib Hydrochloride 15

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Neoplasm Metastasis × monalizumab × Clear all

NCT04307329 2024-10-22

MIMOSA

The Netherlands Cancer Institute

Phase 2 Completed

Breast Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡